secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001650664-25-000153
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Q3 net loss narrows to $25.1M; preclinical EDIT-401 shows >90% LDL-C reduction; cash runway extended to Q3 2027
--------------------------------------------------------------------------------

- Net loss of $25.1M ($0.28/sh) vs $62.1M ($0.75/sh) in Q3 2024; collaboration revenue rose to $7.5M from $0.1M on BMS milestone.
- R&D expenses fell 58% to $19.8M; G&A expenses fell 32% to $12.3M, both reflecting reni-cel program discontinuation.
- Cash & securities $165.6M at Sept. 30; $17.8M raised via ATM in Q3; runway extended into Q3 2027, enabling EDIT-401 progression.
- Preclinical data: single dose of EDIT-401 achieved ≥90% LDL-C reduction in NHPs within 48 hours; durability shown in 3-month mouse study.
- On track to file IND/CTA for EDIT-401 by mid-2026; initial human proof-of-concept data expected by year-end 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000153/0001650664-25-000153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066425000153/edit-20251110.htm
  HTML page:      https://secwatch.observer/filing/0001650664-25-000153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer